These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 24793792)

  • 21. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
    Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
    Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
    Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
    Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
    Lan F; Pan Q; Yu H; Yue X
    J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
    Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
    Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line.
    Montaldi AP; Godoy PR; Sakamoto-Hojo ET
    Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():19-29. PubMed ID: 26520369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
    Lamb LS; Bowersock J; Dasgupta A; Gillespie GY; Su Y; Johnson A; Spencer HT
    PLoS One; 2013; 8(1):e51805. PubMed ID: 23326319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
    Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
    Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma.
    Lu C; Wei Y; Wang X; Zhang Z; Yin J; Li W; Chen L; Lyu X; Shi Z; Yan W; You Y
    Mol Cancer; 2020 Feb; 19(1):28. PubMed ID: 32039732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
    Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
    BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stress stimuli induce cancer-stemness gene expression via Sp1 activation leading to therapeutic resistance in glioblastoma.
    Chang KY; Huang CT; Hsu TI; Hsu CC; Liu JJ; Chuang CK; Hung JJ; Chang WC; Tsai KK; Chuang JY
    Biochem Biophys Res Commun; 2017 Nov; 493(1):14-19. PubMed ID: 28939040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.
    Goellner EM; Grimme B; Brown AR; Lin YC; Wang XH; Sugrue KF; Mitchell L; Trivedi RN; Tang JB; Sobol RW
    Cancer Res; 2011 Mar; 71(6):2308-17. PubMed ID: 21406402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
    Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
    J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
    Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
    Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elimination of cancer stem-like cells and potentiation of temozolomide sensitivity by Honokiol in glioblastoma multiforme cells.
    Lai IC; Shih PH; Yao CJ; Yeh CT; Wang-Peng J; Lui TN; Chuang SE; Hu TS; Lai TY; Lai GM
    PLoS One; 2015; 10(3):e0114830. PubMed ID: 25763821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma.
    Vartanian A; Agnihotri S; Wilson MR; Burrell KE; Tonge PD; Alamsahebpour A; Jalali S; Taccone MS; Mansouri S; Golbourn B; Aldape KD; Zadeh G
    Oncotarget; 2016 Oct; 7(43):69518-69535. PubMed ID: 27588472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HMGA1 silencing reduces stemness and temozolomide resistance in glioblastoma stem cells.
    Colamaio M; Tosti N; Puca F; Mari A; Gattordo R; Kuzay Y; Federico A; Pepe A; Sarnataro D; Ragozzino E; Raia M; Hirata H; Gemei M; Mimori K; Del Vecchio L; Battista S; Fusco A
    Expert Opin Ther Targets; 2016 Oct; 20(10):1169-79. PubMed ID: 27486901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins.
    Kitange GJ; Mladek AC; Schroeder MA; Pokorny JC; Carlson BL; Zhang Y; Nair AA; Lee JH; Yan H; Decker PA; Zhang Z; Sarkaria JN
    Cell Rep; 2016 Mar; 14(11):2587-98. PubMed ID: 26972001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.